Plus Therapeutics Inc. (NASDAQ:PSTV) has a beta value of 0.37 and has seen 2.15 million shares traded in the last trading session. The company, currently valued at $24.80M, closed the last trade at $1.99 per share which meant it lost -$0.06 on the day or -2.93% during that session. The PSTV stock price is -172.36% off its 52-week high price of $5.42 and 10.05% above the 52-week low of $1.79. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.26 million shares traded. The 3-month trading volume is 1.28 million shares.
The consensus among analysts is that Plus Therapeutics Inc. (PSTV) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.24.
Plus Therapeutics Inc. (NASDAQ:PSTV) trade information
Sporting -2.93% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the PSTV stock price touched $1.99 or saw a rise of 13.48%. Year-to-date, Plus Therapeutics Inc. shares have moved -1.49%, while the 5-day performance has seen it change 5.29%. Over the past 30 days, the shares of Plus Therapeutics Inc. (NASDAQ:PSTV) have changed 3.65%. Short interest in the company has seen 0.97 million shares shorted with days to cover at 0.46.
Wall Street analysts have a consensus price target for the stock at $6.50, which means that the shares’ value could jump 69.38% from current levels. The projected low price target is $6.00 while the price target rests at a high of $7.00. In that case, then, we find that the current price level is -251.76% off the targeted high while a plunge would see the stock gain -201.51% from current levels.
Plus Therapeutics Inc. (PSTV) estimates and forecasts
Figures show that Plus Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -21.65% over the past 6 months, with this year growth rate of 47.31%, compared to 18.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 38.50% and 62.70% for the next quarter.
Plus Therapeutics Inc. is expected to release its next earnings report between October 20 and October 25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Plus Therapeutics Inc. (NASDAQ:PSTV)’s Major holders
Insiders own 1.33% of the company shares, while shares held by institutions stand at 2.25% with a share float percentage of 2.28%. Investors are also buoyed by the number of investors in a company, with Plus Therapeutics Inc. having a total of 25 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 0.12 million shares worth more than $0.29 million. As of Mar 30, 2021, Blackrock Inc. held 0.57% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 77086.0 shares as of Mar 30, 2021. The firm’s total holdings are worth over $0.19 million and represent 0.37% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Mar 30, 2021, the former fund manager holds about 0.37% shares in the company for having 77086.0 shares of worth $0.19 million while later fund manager owns 6336.0 shares of worth $15206.0 as of Mar 30, 2021, which makes it owner of about 0.03% of company’s outstanding stock.